Is Kuros Biosciences AG (CSBTF) a Buy, Sell, or Hold?
OTC : CSBTF
Kuros Biosciences AG
$25.5696 USD
$0 (0.0%)
- Volume
- 500
- Average Volume
- 57
- Market Capitalization
- $1.01B
- P/E Ratio
- 464.79
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $42.81
- Year Low
- $22.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.96
Company Overview
OTC
Christopher T. Fair
Biotechnology
Healthcare
CSBTF
178
CH
USD
Liquidity Metrics
0.06
1.96
1.45
0.47
0.00
Sales & Valuation
$121.36M
6.03
11.58
-275.88
-0.07
Profitability
$0.0512
$2.12M
1.26%
3.12%
2.28%
1.53%
P/E Metrics
464.79
9.10
9.10
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
11.93
4/9
$23.38M
$107.26M
$49.39M
$4.57M
Key Metrics (TTM)
$787.32M
6.08
77.21
1.96
2.28%
4.00%
0.21%
-0.35%
$1.27
219 days
Company Executives
| Name | Title |
|---|---|
| Carly Dummer | Senior Director of Marketing |
| G. Joseph Ross | Senior Vice President of Marketing & Business Development |
| Philippe Saudan | Senior Vice President of Quality, Regulatory & Clinical |
| Sjoerd Musters | Executive Officer |
| Laura Rosa | Senior Vice President of Global Human Resources |
| Virginia Jamieson | Consultant |
| Christopher T. Fair | Chief Executive Officer & Director |
| Daniel Geiger | Chief Financial Officer |
| Harry Thomas Hall | Chief Operating Officer |
| John Griffin | Chief Business Officer |
| Joost D. de Bruijn | President of Innovation and Strategy & Executive Director |
Poll Results
No votes yet today — be the first to share your view!
About Kuros Biosciences AG (OTC:CSBTF) Stock
Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau ... fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.
Kuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
2026-06-17 15:02:09
Kuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
2026-06-17 01:00:00
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
2026-05-07 01:00:00
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Frequently Asked Questions
-
What is the current Kuros Biosciences AG (CSBTF) stock price?
-
Kuros Biosciences AG(OTC:CSBTF) stock price is $25.5696 in the last trading session. During the trading session, CSBTF stock reached the peak price of $42.81 while $22.72 was the lowest point it dropped to. The percentage change in CSBTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CSBTF stock was $0.
-
CSBTF's industry and sector of operation?
-
The OTC listed CSBTF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CSBTF?
-
Carly Dummer | Senior Director of Marketing
G. Joseph Ross | Senior Vice President of Marketing & Business Development
Philippe Saudan | Senior Vice President of Quality, Regulatory & Clinical
Sjoerd Musters | Executive Officer
Laura Rosa | Senior Vice President of Global Human Resources -
How many employees does CSBTF have?
-
Number of CSBTF employees currently stands at 178. CSBTF operates from Wagistrasse 25, Schlieren, ZH 8952, CH.
-
Link for CSBTF official website?
-
Official Website of CSBTF is: https://kurosbio.com
-
How do I contact CSBTF?
-
CSBTF could be contacted at phone #41 44 733 4747 and can also be accessed through its website. CSBTF operates from Wagistrasse 25, Schlieren, ZH 8952, CH.
-
How many shares of CSBTF are traded daily?
-
The average number of CSBTF shares traded daily for last 3 months was 57.
-
What is the market cap of CSBTF currently?
-
The market value of CSBTF currently stands at $1.01B with its latest stock price at $25.5696